3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
14
Phase 1
7
Phase 3
5
Phase NA
2
Phase 4
1
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
3
NIH
3
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
438
Neoplasms
363
Breast Neoplasms
261
Colorectal Neoplasms
244
Neoplasm Metastasis
216
Melanoma
210
Leukemia, Myeloid, Acute
188
Multiple Myeloma
187
Pancreatic Neoplasms
182
Ovarian Neoplasms
181
Recurrence
175
Prostatic Neoplasms
161
Lymphoma, Non-Hodgkin
142
Stomach Neoplasms
133
Squamous Cell Carcinoma of Head and Neck
128
Lung Neoplasms
125
Lymphoma
121
Carcinoma, Hepatocellular
117
Carcinoma, Renal Cell
102
Triple Negative Breast Neoplasms
100
Leukemia, Lymphocytic, Chronic, B-Cell
99
Glioblastoma
97
Advanced Solid Tumor
94
Leukemia
93
Small Cell Lung Carcinoma
91
Lymphoma, Large B-Cell, Diffuse
90
Head and Neck Neoplasms
87
Advanced Solid Tumors
85
Endometrial Neoplasms
81
Myelodysplastic Syndromes
78
Interventions
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
INDUSTRY
×
Acquired Immunodeficiency Syndrome
×
Clear all
NCT02229981
2017-12-07
ABC-102
RedHill Biopharma Limited
Phase 1/2
Withdrawn